Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Cognition Therapeutics, Inc. - Common Stock (NQ:CGTX)

1.060 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cognition Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
Cognition Therapeutics to Report Fourth Quarter and Full Year 2022 Results
Conference Call and Live Audio Webcast Scheduled for Wednesday, March 23, 2023, 8:00 a.m. ET 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces Development Plans for Oral CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics to Present at the 33rd Annual Oppenheimer & Co Annual Healthcare Conference
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cognition Therapeutics and ACTC Receive FDA Clearance for Phase 2 START Study of Oral CT1812 in Early Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces New Episode of “Conversations” Podcast: What if it’s not Alzheimer’s? The Caregiver’s Perspective on Lewy Body Dementia
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Completes Enrollment of CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer’s Disease
Innovative Trial Explores Theta Wave qEEG as a Biomarker of Synaptic Dysfunction 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces New “Conversations” Podcast Episode on Key Insights from Recent Clinical Trials in Alzheimer’s Disease
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces Participation in Sachs 6th Annual Neuroscience Forum, Biotech Showcase, and BIO Partnering @ JPM During "J.P. Morgan Week 2023"
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
First Participant Dosed in Europe as Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Clinical Trial of Oral CT1812
SHINE Study Expanded from USA to Include sites in Spain, the Netherlands, and Czech Republic 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24. Vapotherm, Inc. (NASDAQ: VAPO) gained 48.8% to $1.3250. 
Via Benzinga
News headline image
Why Okta Shares Are Trading Higher By Around 14%; Here Are 27 Stocks Moving Premarket ↗
Gainers Pacifico Acquisition Corp. (NASDAQ: PAFO) shares rose 40.9% to $7.58 in pre-market trading after dipping around 43% on Wednesday. 
Via Benzinga
News headline image
Cognition Therapeutics Highlights Phase 2 SHIMMER Study of CT1812 in Dementia with Lewy Bodies in Presentation at CTAD
Innovative trial addresses second most common dementia after Alzheimer’s disease, now enrolling patients at up to 30 activated sites across the USA 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Cognition Therapeutics Launches Neuroscience Thought Leader Conversations Podcast/Webinar Series
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday ↗
Gainers AEye, Inc. (NASDAQ: LIDR) shares jumped 50% to close at $1.25 on Friday. AEye recently posted a Q3 loss of $0.11 per share. 
Via Benzinga
News headline image
$1.8 Million Bet On Cognition Therapeutics? Check Out These 4 Penny Stocks Insiders Are Buying ↗
The Nasdaq Composite dropped by around 175 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
News headline image
Cognition Therapeutics Announces Closing of Public Offering
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Announces Pricing of Public Offering
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving Premarket ↗
Gainers Selina Hospitality PLC (NASDAQ: SLNA) rose 31.9% to $19.90 in pre-market trading after dipping around 63% on Friday. 
Via Benzinga
News headline image
Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday ↗
Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday. 
Via Benzinga
News headline image
Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare & Medicaid Services for the ProSense breast... 
Via Benzinga
News headline image
Cognition Therapeutics is Recruiting for Lewy Body Dementia Phase 2 SHIMMER Trial in Seventeen Research Sites Across the U.S.
Estimated Over 1.4 Million Americans Suffer from LBD – Often Misdiagnosed – No Approved Treatments 
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
From Cognition Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
News headline image
Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.